ORIGINAL RESEARCH

Coronary artery bypass graft versus percutaneous coronary intervention in acute heart failure

Sang Eun Lee,[1] Hae-Young Lee,[2] Hyun-Jai Cho,[2] Won-Seok Choe,[2] Hokon Kim,[2] Jin Oh Choi,[3] Eun-Seok Jeon,[3] Min-Seok Kim,[1] Kyung-Kuk Hwang,[4] Shung Chull Chae,[5] Sang Hong Baek,[6] Seok-Min Kang,[7] Dong-Ju Choi,[8] Byung-Su Yoo,[9] Kye Hun Kim,[10] Myeong-Chan Cho,[4] Jae-Joong Kim,[1] Byung-Hee Oh[2]

ABSTRACT
Objective Myocardial ischaemia is a leading cause of acute heart failure (AHF). However, optimal revascularisation strategies in AHF are unclear. We aimed to compare two revascularisation strategies, coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI), in patients with AHF.
Methods Among 5625 consecutive patients enrolled prospectively in the Korean Acute Heart Failure registry from March 2011 to February 2014, 717 patients who received CABG or PCI during the index hospitalisation for AHF were included in this analysis. We compared adverse outcomes (death, rehospitalisation for HF aggravation or cardiovascular causes, ischaemic stroke and a composite outcome of death and rehospitalisation for HF aggravation or cardiovascular causes) with the use of propensity score matching.
Results For the propensity score-matched cohort with 190 patients, CABG had a lower risk of all-cause mortality than PCI (83 vs 147 deaths per 1000 patient-years; HR 0.57, 95% CI 0.34 to 0.96, p=0.033) during the median follow-up of 4 years. There was also a trend towards lower rates of rehospitalisation due to cardiovascular events or HF aggravation. Subgroup analysis revealed that the adverse outcomes were significantly lower in the CABG group than in PCI group, especially in patients with old age, three-vessel diseases, significant proximal left anterior descending artery disease and those without left main vessel disease or chronic total occlusion.
Conclusions Compared with PCI, CABG is associated with significant lower all-cause mortality in patients with AHF. Further studies should evaluate proper revascularisation strategies in AHF.
Clinical trial registration NCT01389843; Results.

INTRODUCTION
Heart failure (HF) is a global health problem affecting about 26 million people worldwide.[1] Although the aetiology of HF is diverse within and among world regions, coronary artery disease (CAD) is consistently the predominant cause of HF, accounting for as much as 50% of HF cases.[2–4] In those patients, revascularisation is generally accepted to improve clinical outcome.[5–8] However, the time and choice of revascularisation are contentious.[9] The condition is more complicated with acute heart failure (AHF), defined as a life-threatening medical condition with rapid onset or worsening of symptoms and/or signs of HF requiring urgent evaluation and treatment.[10] Most patients with HF experience episodes of AHF throughout the course of their disease and CAD is its leading precipitating factor,[2 11] especially when the aetiology of HF is ischaemic heart disease.[3] Early revascularisation seems to improve clinical outcomes of those patients[8 12 13] and current guidelines recommend an immediate invasive strategy with intent to perform revascularisation in patient with both AHF and acute coronary syndrome (ACS).[14 15] However, the preferred strategy of revascularisation remains unclear.

Strategies for revascularisation in patients with multivessel CAD include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Which one is better has been long debated. Many trials comparing them have shown that the rates of most adverse clinical outcomes are lower after CABG than after PCI,[16–21] thus the current guidelines recommend CABG as the preferred revascularisation strategy in patients with multivessel diseases.[22 23] However, in these trials only a small portion of patients with chronic ambulatory HF with reduced left ventricular ejection fraction (LVEF) were included. Patients with severe congestive HF were excluded. In patients with AHF, especially that precipitated by ACS, the surgical risk might be higher than usual, and surgery might delay revascularisation. On the other hand, PCI may be related to additional risk for contrast-induced nephropathy and volume overload, which might complicate the clinician's decision. Here, to investigate the better strategy for revascularisation in patients with AHF, we compared long-term clinical outcome of the patients who received CABG or PCI during the hospitalisation for AHF with the use of propensity score matching.

METHODS
Patients, data collection and outcome
The Korean Acute Heart Failure registry is a prospective, multicentre, cohort study designed to describe demographic and clinical profiles, current diagnostic approaches and treatments and short-term and long-term patient outcomes of AHF in Korea. Detailed information on the study design and the main results has been described.[2 3] Briefly, 5625 patients hospitalised for AHF from 10 tertiary

university hospitals throughout the country were consecutively enrolled from March 2011 to February 2014. Among them, 717 patients who received one of the two revascularisation strategies (590 PCIs and 127 CABGs) during the index hospitalisation were included in this analysis. Four patients who had rescue CABG immediately after PCI, because of complications of PCI, were excluded. Information on patient demographics, medical history, signs and symptoms, results of laboratory tests, ECG results, echocardiography results, coronary angiographic results, medications, procedures and outcomes at admission and discharge were included in this analysis. The primary end point was all-cause death after procedure or after discharge. The secondary outcome was rehospitalisation due to HF aggravation, rehospitalisation due to cardiovascular causes, composite outcome of all-cause death and rehospitalisation due to cardiovascular causes or HF aggravation, length of hospital stay, in-hospital all-cause death, in-hospital cardiovascular death and stroke. Written informed consent was obtained from each patient at the early phase of this study; however, the institutional review boards at each hospital waived the requirement for informed consent because this study was initiated and sponsored by the Korean Ministry of Health and Welfare to improve public healthcare and had minimal risk for the patients.

Statistical analyses

Descriptive statistics were used for clinical and laboratory characteristics. Data are presented as numbers and percentages for categorical variables and mean±SD deviation for continuous variables. Baseline characteristics of the two intervention groups were compared with the independent t-test, or the Wilcoxon rank sum test for continuous variables as appropriate, and the X^2 test for categorical variables. To reduce the effect of treatment-selection bias and potential confounding in this observational study, we performed rigorous adjustment for significant differences in the baseline characteristics of patients with the use of propensity score matching.[24 25] A propensity score for CABG versus PCI was calculated. The propensity score was estimated without regard to outcome variables using a logistic regression model. All prespecified covariates (table 1) were included in the final models for treatment with CABG versus PCI. A propensity score indicating the predicted probability of receiving a specific treatment conditional on the observed covariates was then calculated for each patient from the logistic equation. The predictive ability of the propensity score model was assessed using c-statistic (0.883). The p value of Hosmer and Lemeshow goodness-of-fit test was 0.9784. We created propensity score-matched pairs without replacement (1:1 match), and 95 patients with PCI and 95 patients with CABG were matched. After all the propensity score matches were performed, we assessed the balance in baseline covariates between the two intervention groups with the paired t-test or the Wilcoxon signed rank test for continuous variables, and the McNemar's test or Bowker's test of symmetry test for categorical variables and also with standardised difference. The risks of in-hospital all-cause death, cardiovascular death, stroke and the length of hospital stay were compared with the use of generalised estimating equations (GEE) treating each pair as a cluster. The postprocedure all-cause death or the postdischarge risk for each outcome were compared with the use of Cox regression models considering the clustering effect based on robust sandwich covariance matrix estimate that accounted for the clustering of matched pairs. Survival curves were constructed with Kaplan-Meier estimates. All reported p values are two-sided and p<0.05 was considered to indicate statistical significance.

SAS software, V.9.1, and the R programming language were used for statistical analyses. The statistical analyses were performed by professional statisticians affiliated to the Medical Research Collaborating Center at the Seoul National University College of Medicine and the Seoul National University Hospital.

RESULTS

Patients and baseline characteristics

Between March 2011 and February 2014, 5625 patients were hospitalised for AHF at 10 tertiary university hospitals throughout Korea. Among them, 590 patients received PCI and 127 patients had CABG during the index hospitalisation. Drug-eluting stents were used in most PCI cases and 15 patients received bare-metal stents. The baseline clinical and coronary angiographic characteristics of the PCI and CABG groups are compared in table 1. Those who received CABG were younger, more likely to be male and to have diabetes, but were less likely to have hypertension and myocardial infarction. They had lower blood pressure, lower LVEF and higher serum creatinine levels at admission. Leucocytosis, hyponatraemia and high levels of natriuretic peptides were more prevalent in the CABG group. Furthermore, three-vessel diseases, left main lesion, proximal left anterior descending lesion and chronic total occlusion were more frequent in patients who received CABG. After propensity score matching, there were 190 matched patients (table 1), and the distribution of propensity scores was essentially identical (see online supplementary figure 1). However, because the standardised differences for sex, New York Heart Association class, hypertension, diabetes, other intraventricular conduction delay, hyponatraemia, use of beta-blockers and number of diseased vessels were larger than 0.1, we adjusted for these variables in our final model.

Clinical outcomes

Table 2 presents the short-term and long-term clinical outcomes according to the treatment strategy in the overall and matched cohorts. In the overall cohort, in-hospital mortality rate was 8.1% for the PCI group and 7.9% for the CABG group. The median follow-up duration for all-cause death was 1368 days for the PCI group and 1462 days for the PCI group in the overall cohort. The PCI group had 131 (95% CI 114 to 149) deaths per 1000 patient-years vs 81 (95% CI 56 to 113) in the CABG group (p=0.008). The unadjusted HR favoured the CABG group (0.62, 95% CI 0.44 to 0.90, p=0.011). Rehospitalisation for cardiovascular problems was 205 (95% CI 178 to 235) and 144 (95% CI 102 to 198) per 1000 patient-years for the PCI and CABG groups, respectively (p=0.048). Rehospitalisation for HF aggravation was 117 (95% CI 98 to 139) per 1000 patient-years for PCI group and 91 (95% CI 59 to 133) for the CABG group (p=0.278). The unadjusted HRs for rehospitalisation for cardiovascular problems and HF aggravation were 0.76 and 0.82, respectively, which was not significant. The repeat revascularisation rate during follow-up was significantly lower in the CABG group than in the PCI group (HR 0.41, 95% CI 0.18 to 0.94, p=0.035).

In the matched cohort, in-hospital mortality rate was 10.5% for the PCI group and 5.3% for the CABG group. The OR estimated by GEE was 0.47 (95% CI 0.15 to 1.50, p=0.203). ORs for in-hospital cardiovascular death and stroke were 0.37 (95% CI 0.11 to 1.29, p=0.118) and 0.48 (95% CI 0.11 to 2.06, p=0.325), respectively. Mean duration of hospital stay was 14 and 33 days for the PCI and CABG group, respectively (p<0.001) (table 2). The median follow-up duration after

Table 1 The baseline clinical and coronary angiographic characteristics

	Overall cohort				Propensity score-matched cohort			
	PCI group (n=590)	CABG group (n=127)	P values	Standardised difference	PCI group (n=95)	CABG group (n=95)	P values	Standardised difference
Demographic characteristics								
Age, years	70.7±11.4	68.3±10.6	0.018†	0.216	69.2±11.5	69.0±10.0	0.917‡	0.015
Male	373 (63.2)	97 (76.4)	0.005	−0.290	78 (82.1)	70 (73.7)	0.201	0.204
Smoking	138 (23.4)	35 (27.6)	0.319	−0.096	23 (24.2)	24 (25.3)	1.000	−0.024
Body mass index, kg/m^2	23.4±3.4	23.3±3.2	0.529†	0.018	23.4±2.9	23.3±3.3	0.719‡	0.050
De novo HF	447 (75.8)	95 (74.8)	0.819	−0.022	67 (70.5)	69 (72.6)	0.871	0.047
Comorbidities								
Hypertension	420 (71.2)	79 (62.2)	0.046	0.191	65 (68.4)	60 (63.2)	0.568	0.111
Diabetes	338 (57.3)	93 (73.2)	<0.001	−0.340	61 (64.2)	68 (71.6)	0.360	−0.158
Myocardial infarction	410 (69.5)	63 (49.6)	<0.001	−0.361	51 (53.7)	49 (51.6)	0.974	−0.021
Atrial fibrillation	113 (19.2)	25 (19.7)	0.890	−0.013	19 (20.0)	16 (16.8)	0.720	0.082
Chronic renal insufficiency	83 (14.1)	19 (15.0)	0.794	0.025	18 (19.0)	15 (15.8)	0.701	−0.083
Chronic lung disease	51 (8.6)	14 (11.0)	0.397	0.080	12 (12.6)	12 (12.6)	1.000	0
Cerebrovascular disease	90 (15.3)	18 (14.2)	0.757	−0.031	17 (17.9)	15 (15.8)	0.845	−0.056
History of malignancy	37 (6.3)	8 (6.3)	0.991	0.001	6 (6.3)	7 (7.4)	1.000	0.042
Clinical status								
Systolic blood pressure	132.6±31.3	123.8±23.8	<0.001*	0.317	123.9±27.9	124.4±22.2	0.884‡	−0.021
Diastolic blood pressure	78.4±17.8	72.6±15.4	<0.001*	0.346	72.4±14.7	72.5±15.4	0.846§	−0.010
Pulse rate	91.8±23.8	93.0±21.7	0.753†	−0.051	92.6±22.1	92.3±22.8	0.912‡	0.015
NYHA functional class			0.2582				0.8516	
II	82 (13.9)	23 (18.1)			13 (13.7)	12 (12.6)		
III	171 (29.0)	41 (32.3)		−0.072	30 (31.6)	35 (36.8)		−0.111
IV	337 (57.1)	63 (49.6)		0.151	52 (54.7)	48 (50.5)		0.084
Lung congestion	469 (79.5)	100 (78.7)	0.850	−0.018	74 (77.9)	74 (77.9)	1.000	0
Laboratory test								
LVEF, %	37.8±12.3	32.6±12.0	<0.001†	0.426	34.3±11.7	33.4±12.6	0.629‡	0.073
Leucocytosis (WBC>10 000/mm^3)	251 (42.5)	39 (30.7)	0.014	0.248	31 (32.6)	30 (31.6)	1.000	0.023
Hyponatraemia (<135 mmol/L)	89 (15.1)	30 (23.6)	0.019	0.217	79 (83.2)	75 (79.0)	0.597	0.108
Anaemia (haemoglobin<12 g/dL)	256 (43.4)	48 (37.8)	0.247	−0.114	54 (56.8)	56 (59.0)	0.885	−0.043
Serum creatinine, mg/dL	1.6±1.7	1.6±1.5	0.543†	0.050	1.7±1.4	1.6±1.7	0.214§	0.039
BNP≥500 pg/mL or NT-proBNP≥1000, pg/mL	387 (65.6)	95 (74.8)	0.005	−0.202	69 (72.6)	70 (73.7)	0.902	−0.024
ECG								
Q wave	162 (27.5)	44 (34.7)	0.104	0.156	32 (33.7)	33 (34.7)	1.000	0.022
Left bundle branch block	29 (4.9)	8 (6.3)	0.526	0.060	6 (6.3)	7 (7.4)	1.000	0.042
Right bundle branch block	39 (6.6)	14 (11.0)	0.085	0.156	8 (8.4)	8 (8.4)	1.000	0
Other intraventricular conduction delay	30 (5.1)	7 (5.5)	0.844	0.019	10 (10.5)	4 (4.2)	0.146	−0.244
Drug therapy before admission								
ACEIs or ARBs	177 (30.0)	60 (47.2)	<0.001	0.360	41 (43.7)	41 (43.2)	1.000	0
Beta-blockers	137 (23.2)	37 (29.1)	0.159	0.135	36 (37.9)	28 (29.5)	0.291	−0.179
Aldosterone antagonists	40 (6.8)	17 (13.4)	0.013	0.221	10 (10.5)	12 (12.6)	0.824	0.066
Coronary lesions								
Number of diseased vessels			<0.001				0.726	
1	141 (23.9)	7 (5.7)			8 (8.4)	7 (7.4)		
2	212 (35.9)	13 (10.5)		0.632	9 (9.5)	13 (13.7)		−0.132
3	237 (40.2)	104 (83.9)		−1.008	78 (82.1)	75 (79.0)		0.080
Left main lesion	81 (13.8)	44 (35.5)	<0.001	−0.521	66 (69.5)	68 (71.6)	0.860	0.046
Proximal LAD lesion	339 (57.6)	92 (74.2)	<0.001	−0.356	68 (71.6)	67 (70.5)	1.000	0.023
Chronic total occlusion	232 (39.3)	73 (58.9)	<0.001	−0.399	52 (54.7)	49 (51.6)	0.761	0.063

Per cent (%) in parentheses.
*P value by independent t-test.
†P value by Wilcoxon rank sum test.
‡P value by paired t-test.
§P value by Wilcoxon signed rank test.
ACEIs, ACE inhibitors; ARBs, angiotensin receptor blockers; BNP, brain natriuretic peptides; CABG, coronary artery bypass graf; HF, heart failure; LAD, left anterior descending; LVEF, left ventricular ejection fraction; New York Heart Association; NT-proBNP, N-terminal pro brain natriuretic peptide; PCI, percutaneous coronary intervention; WBC, white blood cells.

Table 2   Clinical outcomes

	Overall (n=717)			Matched (n=190)		
	PCI	CABG	P values	PCI	CABG	P values
Total, n	590	127		95	95	
In-hospital outcomes						
Death	48 (8.1)	10 (7.9)		10 (10.5)	5 (5.3)	
CABG vs PCI, OR (95% CI)	0.9 (0.5 to 1.9)		0.849	0.47 (0.15 to 1.50)		0.203‡
Cardiovascular death	46 (7.8)	7 (5.3)		10 (10.5)	4 (4.2)	
CABG vs PCI, OR (95% CI)	0.7 (0.3 to 1.5)		0.333	0.37 (0.11 to 1.29)		0.118‡
Stroke	16 (2.7)	4 (3.1)		6 (6.3)	3 (3.2)	
CABG vs PCI, OR (95% CI)	1.1 (0.4 to 3.4)		0.830	0.48 (0.11 to 2.06)		0.325‡
Hospital stay						
Mean±SE (95% CI), days	13.5±0.8	33.0±1.6	<0.001	14.4±1.5	32.9±3.4	<0.001‡
Follow-up time						
Total patient-years	1776	419		279	323	
Median, days						
Death	1368	1462		1383	1468	
Rehospitalisation for CV	489	977		375	966	
Rehospitalisation for HF aggravation	776	1080		714	1075	
Composite of death and CV rehospitalisation	734	1243		681	1238	
Composite of death and HF rehospitalisation	1153	1339		1258	1388	
Repeat revascularisation during follow-up	907	1171		767	1178	
Cumulative outcomes, n (%)						
Death	232 (42.8)	34 (29.1)		41 (48.2)	27 (30.0)	
Rehospitalisation for CV	203 (37.5)	38 (32.5)		37 (43.5)	30 (33.3)	
Rehospitalisation for HF aggravation	135 (24.9)	26 (22.2)		22 (25.9)	19 (21.1)	
Composite of death and CV rehospitalisation	341 (62.9)	55 (47.0)		59 (69.4)	44 (48.9)	
Composite of death and HF rehospitalisation	293 (54.1)	47 (40.2)		49 (57.7)	37 (41.1)	
Repeat revascularisation during follow-up	58 (10.7)	6 (5.1)		15 (17.7)	4 (4.4)	
Main analysis, outcomes compared						
Death						
Events per 1000 patient-years, n (95% CI)	131 (114 to 149)	81 (56 to 113)	0.008*	147 (105 to 199)	83 (55 to 121)	0.028*
CABG vs PCI, HR (95% CI)	0.62 (0.44 to 0.90)		0.011	0.57 (0.34 to 0.96)		0.033†
Rehospitalisation for CV						
Events per 1000 patient-years, n (95% CI)	205 (178 to 235)	144 (102 to 198)	0.048*	261 (183 to 359)	151 (102 to 216)	0.026*
CABG vs PCI, HR (95% CI)	0.76 (0.54 to 1.08)		0.129	0.67 (0.39 to 1.15)		0.146†
Rehospitalisation for HF aggravation						
Events per 1000 patient-years, n (95% CI)	117 (98 to 139)	91 (59 to 133)	0.278*	125 (79 to 190)	86 (52 to 134)	0.271*
CABG vs PCI, HR (95% CI)	0.82 (0.54 to 1.25)		0.365	0.76 (0.40 to 1.44)		0.399†
Composite of death and CV rehospitalisation						
Events per 1000 patient-years, n (95% CI)	268 (240 to 298)	170 (128 to 221)	0.001*	306 (233 to 395)	181 (132 to 243)	0.010*
CABG vs PCI, HR (95% CI)	0.68 (0.51 to 0.90)		0.007	0.65 (0.42 to 1.01)		0.053†
Composite of death and HF rehospitalisation						
Events per 1000 patient-years, n (95% CI)	198 (176 to 222)	132 (97 to 175)	0.008*	209 (155 to 76)	135 (95 to 186)	0.051*
CABG vs PCI, HR (95% CI)	0.70 (0.51 to 0.95)		0.021	0.68 (0.43 to 1.07)		0.093†
Repeat revascularisation during follow-up						
Events per 1000 patient-years, n (95% CI)	46 (35 to 60)	18 (7 to 39)	0.021*	82 (46 to d135)	15 (4 to 40)	0.002*
CABG vs PCI, HR (95% CI)	0.41 (0.18 to 0.94)		0.035	0.19 (0.06 to 0.60)		0.004†

*P value by exact Poisson test.
†P value by Cox regression models considering the clustering effect based on robust sandwich covariance matrix estimate that accounted for the clustering of matched pairs.
‡P value by generalised estimating equations treating each pair as a cluster.
CABG, coronary artery bypass graft; CV, cardiovascular; HF, heart failure, PCI, percutaneous coronary intervention.

discharge from index hospitalisation was 1383 days for the PCI group and 1468 days for the CABG group in the matched cohort. During the follow-up period, the PCI group had 147 (95% CI 105 to 199) deaths per 1000 patient-years vs 83 (95% CI 55 to 121) in the CABG group (p=0.028) favouring CABG (HR 0.57, 95% CI 0.34 to 0.96, p=0.033) (figure 1A). The result was identical even when we estimated the mortality based on the date of revascularisation, but not based on the date of discharge (HR 0.54, 95% CI 0.35 to 0.85, p=0.008, figure 1B). Rehospitalisation for cardiovascular problems was 261 (95% CI 183 to 359) and 151 (95% CI 102 to 216) per 1000 patient-years for the PCI and CABG groups, respectively (p=0.026). Rehospitalisation for HF aggravation was 125 (95% CI 79 to 190) per 1000 patient-years for the PCI group and 86 (95% CI

Figure 1 Kaplan-Meier curves in the matched and overall cohorts. Long-term clinical outcomes in total population and in the matched cohort. (A) All-cause death after discharge. (B) All-cause death after the revascularisation procedure. (C) Rehospitalisation for cardiovascular problems. (D) Rehospitalisation for heart failure aggravation. (E) All-cause death and rehospitalisation for cardiovascular problems. (F) All-cause death and rehospitalisation for heart failure aggravation. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.

52 to 134) for the CABG group (p=0.271). HRs for rehospitalisation for cardiovascular problems and HF aggravation were 0.67 (95% CI 0.39 to 1.15, p=0.146) and 0.76 (95% CI 0.40 to 1.44, p=0.399), respectively (figure 1C,D). The unadjusted HRs for a composite outcome of death and rehospitalisation for either cardiovascular causes or HF aggravation were 0.65 (95% CI 0.42 to 1.01, p=0.053) and 0.68 (95% CI 0.43 to 1.07, p=0.093), respectively (figure 1E,F). The repeat revascularisation rate was 82 (95% CI 46 to 135) per 1000 patient-years for PCI group and 15 (95% CI 4 to 40) per 1000 patient-years for the CABG group (p=0.002). The unadjusted HR for repeat revascularisation in the matched cohort was 0.19 (95% CI 0.06 to 0.60, p=0.004) (supplementary figure 2).

Since prescription of ACE inhibitors/angiotensin receptor blockers (ACEIs/ARBs), beta-blockers and aldosterone antagonists were not matched between the groups, there were significant differences in their use at discharge (table 3). ACEIs/ARBs and beta-blockers were more frequently described in the PCI group compared with the CABG group (64.2% vs 43.2%, p=0.008 for ACEIs/ARBs; 63.2% vs 47.4%, p=0.082 for beta-blockers). After adjusting these variables, all-cause mortality after discharge and after the procedure remained significantly lower in the CABG group (HR 0.51, 95% CI 0.30 to 0.88, p=0.016 after discharge and HR 0.57, 95% CI 0.36 to 0.91, p=0.018 after procedure). Moreover, because there were several covariates with standardised differences larger than 0.1 even after propensity score matching, aside from the drug therapies, we included these factors in the final Cox proportional HR model together with drug therapy at discharge. This analysis revealed that even after adjustment, CABG was still significantly associated with

Table 3 Drug therapy at discharge

	Overall cohort				Propensity score-matched cohort			
	PCI group (n=590)	CABG group (n=127)	P values	Standardised difference	PCI group (n=95)	CABG group (n=95)	P values	Standardised difference
Drug therapy at discharge								
ACEIs or ARBs	387 (65.6)	58 (45.7)	<0.001	−0.409	61 (64.2)	41 (43.2)	0.008	−0.432
Beta-blockers	382 (64.8)	59 (46.5)	<0.001	−0.375	60 (63.2)	45 (47.4)	0.082	−0.322
Aldosterone antagonists	200 (33.9)	58 (45.7)	0.012	0.242	36 (37.9)	42 (44.2)	0.480	0.129

Per cent (%) in parentheses.

ACEIs, ACE inhibitors; ARBs, angiotensin receptor blockers; CABG, coronary artery bypass graft; HF, heart failure; PCI, percutaneous coronary intervention.

decreased all-cause mortality after the procedure as well as after discharge in comparison to PCI (HR 0.53; 95% CI 0.31 to 0.90; p=0.020 for mortality after discharge and HR 0.45; 95% CI 0.27 to 0.74; p=0.002 for mortality after the procedure).

Subgroup outcomes

Subgroup analysis was performed to determine the impact of CABG on death according to the characteristics of the patients and the coronary lesions. Figure 2 and online supplementary figure 3 depict the HRs for mortality associated with CABG in clinically relevant prespecified subgroups and the p values for interaction between the revascularisation strategy and the covariates. Although there were no significant interactions, lower risk with CABG was statistically significant, especially in elderly patients, those with three-vessel diseases, significant proximal left anterior descending artery disease and those without left main vessel disease or chronic total occlusion.

DISCUSSION

In this propensity score-matched comparison between PCI and CABG in patients admitted for AHF, the rate of death from any cause over 4 years was lower by 40% among patients

who underwent CABG than among those who received PCI. As anticipated, CABG was associated with longer hospital stay. Thus, to exclude bias from the time lag incurred by the further hospital stay in the CABG group, we analysed mortality based on the date of revascularisation instead of the date of discharge to yield identical results. Although there was no significant difference between the groups with respect to rehospitalisation for cardiovascular causes or for HF aggravation, there was a trend favouring CABG over PCI across all clinically relevant outcomes we evaluated. We believe the numbers of cases and controls or the follow-up duration were not enough to show a statistical significance for the secondary outcomes. The divergence of the curves over the period of follow-up supports our hypothesis and underscores the lasting benefits of CABG over PCI.[5 6]

In the overall cohort, CABG was associated with lower LVEF and severe coronary lesions as expected. Thus, the characteristics of the patients in the matched cohort were similar to those of CABG group in the overall cohort, showing lower LVEF and severe coronary lesions. Although there was no interactions among the subgroups, the benefit of CABG was associated with the extent of CAD. This is consistent with previous

Figure 2 Interaction and HR for all-cause death after discharge in prespecified subgroups in the matched cohort. DM, diabetes mellitus; IHD, ischaemic heart disease; LAD, left anterior descending; LVEF, left ventricular ejection fraction.

reports, which indicated a greater benefit of CABG in patients with three-vessel CAD than among patients with one-vessel or two-vessel disease.[16 19 21 26] This might be attributable to the different ability of each revascularisation strategy to achieve complete revascularisation in extensive CADs as some believe that late outcome is influenced by the completeness of revascularisation but not by the method.[27] The complete revascularisation rate, defined as all stenotic main-branch vessels being revascularised,[28] was significantly higher in the CABG group than in the PCI group in our matched cohort (72.4% vs 43.5%, p<0.001). Although the adverse outcomes were significantly lower in the CABG group than in the PCI group, especially in more elderly patients, those with significant proximal left anterior descending artery disease, and those without left main vessel disease or chronic total occlusion, the trends were similar all favouring CABG than PCI, and the statistical significance was related to the number of patients and events.

A recent report by the Surgical Treatment for Ischaemic Heart Failure trial supported the decision for revascularisation in patients with CAD associated with left ventricular dysfunction. However, there were few direct comparisons between PCI versus CABG in patients with left ventricular dysfunction. In an analysis from a cohort of patients who received revascularisation and had a history of HF, patients undergoing CABG appeared to have slightly better survival than those who received PCI.[29] However, this cohort was not intended to enrol patients with HF but rather patients who received coronary angiography, and the patients were selected based on history of HF. Therefore, only 7.7% of those who received revascularisation had HF as the primary indication for catheterisation. The Heart Failure Revascularisation trial evaluated whether revascularisation improves the survival of patients with HF due to CAD.[30] Patients with LVEF <35% requiring chronic diuretic therapy and with evidence of at least five segments being affected by ischaemia and/or hibernation were included. Any conventional revascularisation strategy was permitted. However, only 138 of the planned 800 patients were enrolled owing to problems with recruitment and funding, and the study was stopped early. There were no differences in the incidence of all-cause mortality and in quality of life. Therefore, this is the first analysis supporting the advantage of CABG over PCI for survival of the patients hospitalised for AHF with CAD, especially those with multivessel diseases.

LIMITATIONS
The major limitation of the present study is that it is an observational study. The revascularisation strategy was not based on randomised assignment and so is subject to potential bias with respect to the relative preprocedural severity of illness among patients treated with CABG and PCI. To minimise this bias, we used propensity score matching. Nevertheless, hidden bias may remain because of the influence of unmeasured confounders. For example, one might argue that those who received PCI represents ACS while CABG represents chronic ischaemic cardiomyopathy. However, after propensity score matching there were no significant difference between the groups in prevalence of myocardial infarction or ACS as an aetiology or aggravating factor of HF, respectively (53.7% vs 51.6%, p=0.974, standardised difference=−0.021; 98.9% vs 93.7%, p=0.123, standardised difference=0.123). Even after propensity score matching, there were several covariates with standard difference exceeding 0.1. However, after adjustment of these factors, CABG was still significantly associated with decreased all-cause

mortality compared with PCI. Another caveat is that our analysis was underpowered to detect significant differences in secondary outcomes like rehospitalisation. Finally, the characteristics of the matched population were similar to those of the CABG group in the overall cohort. Therefore, it would not be appropriate to apply our results to the general population with ischaemic heart disease presenting with AHF; instead, our results apply to patients with severe coronary lesions.

CONCLUSION
In a matched cohort of patient with AHF and CAD, CABG was associated with better long-term rate of all-cause death.

Key messages

What is already known on this subject?
► Revascularisation of coronary artery diseases improves clinical outcome of heart failure with ischaemic heart disease.

What might this study add?
► Compared with percutaneous coronary intervention, coronary artery bypass graft is associated with significant lower all-cause mortality in patients with acute heart failure (83 deaths per 1000 patient-years in the coronary artery bypass graft group vs 147 deaths per 1000 patient-years in the percutaneous coronary intervention group (HR 0.57, 95% CI 0.34–0.96, p=0.033), especially when they have multivessel coronary artery diseases (HR 0.46, 95% CI 0.26 to 0.81, p=0.008).

How might this impact on clinical practice?
► This result suggests that coronary artery bypass graft might be preferred in acute heart failure with multivessel coronary artery diseases.

Author affiliations
[1]Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
[2]Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
[3]Sungkyunkwan University College of Medicine, Seoul, Korea
[4]Chungbuk National University College of Medicine, Cheongju, Korea
[5]Kyungpook National University College of Medicine, Daegu, Korea
[6]The Catholic University of Korea, Seoul, Korea
[7]Yonsei University College of Medicine, Seoul, Korea
[8]Seoul National University Bundang Hospital, Seongnam, Korea
[9]Yonsei University Wonju College of Medicine, Wonju, Korea
[10]Heart Research Center of Chonnam National University, Gwangju, Korea

REFERENCES

1 Ambrosy AP, Fonarow GC, Butler J, *et al*. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014;63:1123–33.

2 Lee SE, Cho HJ, Lee HY, *et al*. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. *Eur J Heart Fail* 2014;16:700–8.

3. Lee SE, Lee H-Y, Cho H-J, *et al*. Clinical profiles, management and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). *Korean Circ J* 2017.

4 Lam CS, Teng TK, Tay WT, *et al*. Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. *Eur Heart J* 2016;37:3141–53.

5 Velazquez EJ, Lee KL, Deja MA, *et al*. Coronary-artery bypass surgery in patients with left ventricular dysfunction. *N Engl J Med* 2011;364:1607–16.

6 Velazquez EJ, Lee KL, Jones RH, *et al*. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. *N Engl J Med* 2016;374:1511–20.

7 Allman KC, Shaw LJ, Hachamovitch R, *et al*. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. *J Am Coll Cardiol* 2002;39:1151–8.

8 Rott D, Behar S, Leor J, *et al*. Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. *Am J Cardiol* 2001;88:618–23.

9 Mangiacapra F, De Bruyne B, Wijns W, *et al*. Optimizing revascularization strategies in coronary artery disease for optimal benefit to patients. *Clin Pharmacol Ther* 2011;90:630–3.

10 Ponikowski P, Voors AA, Anker SD, *et al*. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;2016:2129–200.

11 Fonarow GC, Abraham WT, Albert NM, *et al*. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. *Arch Intern Med* 2008;168:847–54.

12 Tavazzi L, Maggioni AP, Lucci D, *et al*. Nationwide survey on acute heart failure in cardiology ward services in Italy. *Eur Heart J* 2006;27:1207–15.

13 Rossi JS, Flaherty JD, Fonarow GC, *et al*. Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). *Eur J Heart Fail* 2008;10:1215–23.

14 Sliwa K, Davison BA, Mayosi BM, *et al*. Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry. *Eur Heart J* 2013;34:3151–9.

15 Amsterdam EA, Wenger NK, Brindis RG, *et al*. AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;2014:e344–426.

16 Serruys PW, Morice MC, Kappetein AP, *et al*. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009;360:961–72.

17 Mohr FW, Morice MC, Kappetein AP, *et al*. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013;381:629–38.

18 Head SJ, Davierwala PM, Serruys PW, *et al*. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. *Eur Heart J* 2014;35:2821–30.

19 Deb S, Wijeysundera HC, Ko DT, *et al*. Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review. *JAMA* 2013;310:2086–95.

20 Weintraub WS, Grau-Sepulveda MV, Weiss JM, *et al*. Comparative effectiveness of revascularization strategies. *N Engl J Med* 2012;366:1467–76.

21 Park SJ, Ahn JM, Kim YH, *et al*. Trial of everolimus-eluting stents or bypass surgery for coronary disease. *N Engl J Med* 2015;372:1204–12.

22 Hillis LD, Smith PK, Anderson JL, *et al*. ACCF/AHA Guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *Circulation* 2011;2011:2610–42.

23 Windecker S, Kolh P, Alfonso F, *et al*. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35:2541–619.

24 Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. *Stat Med* 2009;28:3083–107.

25 Normand ST, Landrum MB, Guadagnoli E, *et al*. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. *J Clin Epidemiol* 2001;54:387–98.

26 Hannan EL, Wu C, Walford G, *et al*. Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med* 2008;358:331–41.

27 Ahn JM, Park DW, Lee CW, *et al*. Comparison of stenting versus bypass surgery according to the completeness of revascularization in severe coronary artery disease: patient-level pooled analysis of the SYNTAX, PRECOMBAT, and BEST Trials. *JACC Cardiovasc Interv* 2017;10:1415–24.

28 Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery versus percutaneous coronary intervention. *Circulation* 2006;114:249–55.

29 Tsuyuki RT, Shrive FM, Galbraith PD, *et al*. Revascularization in patients with heart failure. *CMAJ* 2006;175:361–5.

30 Cleland JG, Calvert M, Freemantle N, *et al*. The Heart Failure Revascularisation Trial (HEART). *Eur J Heart Fail* 2011;13:227–33.